ATHEROSCLEROSIS
NANOBAC
Por vários indícios (conteúdo, modo de apresentação, mercadologia...) parece mais uma dessas tantas panacéias para explorar desesperados, portadores ou assustados com problemas de difícil solução. Entretanto há que anotar para ver até onde pode, algo não mágico, seexconder nesta proposta.
NanobacTX
is a unique patented therapy designed and targeted to REVERSE arteriosclerosis and Heart Disease by dissolving the calcified artery plaque and pathological calcification deposits resident in blood vessels, organs and tissues. Our published cardiology & endovascular studies show that NanobacTX decreases heart disease symptoms, chest pain and increases exercise ability while alleviating inflammation and coronary artery calcification, which IS Heart Disease. NanobacTX was shown to eliminate calcified plaque volume in the coronary arteries after in 6 months of nightly treatment. The studies show that NanobacTX causes the calcified coronary artery plaque to regress & dissolve in a time-dependent fashion to zero calcified plaque. Cardiac-muscle microvascular disease is also eliminated and therefore allows for increased stroke volume/ejection fraction in those with compromised heart pumping ability in disorders like congestive heart failure (CHF).
Por vários indícios (conteúdo, modo de apresentação, mercadologia...) parece mais uma dessas tantas panacéias para explorar desesperados, portadores ou assustados com problemas de difícil solução. Entretanto há que anotar para ver até onde pode, algo não mágico, seexconder nesta proposta.
NanobacTX
is a unique patented therapy designed and targeted to REVERSE arteriosclerosis and Heart Disease by dissolving the calcified artery plaque and pathological calcification deposits resident in blood vessels, organs and tissues. Our published cardiology & endovascular studies show that NanobacTX decreases heart disease symptoms, chest pain and increases exercise ability while alleviating inflammation and coronary artery calcification, which IS Heart Disease. NanobacTX was shown to eliminate calcified plaque volume in the coronary arteries after in 6 months of nightly treatment. The studies show that NanobacTX causes the calcified coronary artery plaque to regress & dissolve in a time-dependent fashion to zero calcified plaque. Cardiac-muscle microvascular disease is also eliminated and therefore allows for increased stroke volume/ejection fraction in those with compromised heart pumping ability in disorders like congestive heart failure (CHF).
Labels: Alzheimer
posted by Aloyzio Achutti at 9:55 AM
0 Comments:
Post a Comment
<< Home